Peter Attia· MD
there've been 52 FDA approvals but um but that's against 19 unique mechanisms right so there's a lot of me a lot of me ISM um I mean this is true in all Therapeutics not just oncology um and so that's so like I I tend to then go down to that number right so like 19 unique mechanisms um and and even there frankly there's not there's some there's some overlap um so like different like your targets but like for the same population like within a given pathway inside a cell there's instances where we've actually successfully drugged like one component and its immediate Downstream component and the immediate Downstream component yet again that would then count as three on that list of 19 but really they're very overlapping so if I were to really boil it down you know I would we're you know kind of in the 10 range um in terms of you know truly unique y uh molecular targets